ObsEva SA (OBSV) Gets a Buy Rating from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ObsEva SA (OBSVResearch Report), with a price target of $17.00. The company’s shares closed last Tuesday at $3.01.

According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.5% and a 39.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, NeuroBo Pharmaceuticals, and Fennec Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ObsEva SA with a $19.00 average price target, implying a 518.9% upside from current levels. In a report issued on September 1, Wedbush also reiterated a Buy rating on the stock with a $21.00 price target.

See today’s analyst top recommended stocks >>

ObsEva SA’s market cap is currently $234.6M and has a P/E ratio of -2.30. The company has a Price to Book ratio of 15.99.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.